Advisory Committee To Revisit Boxed Warning For Protopic, Elidel
This article was originally published in The Pink Sheet Daily
Executive Summary
Six years after recommending boxed warnings and medication guides for Novartis' Elidel (pimecrolimus) and Astellas' Protopic (tacrolimus), the Pediatric Advisory Committee will hear updates on their safety.
You may also be interested in...
Sub-therapeutic Dosing In Pediatric Trials To Be Reviewed By FDA's Pediatric Ethics Subcommittee
Panel is called in to shed light in a growing but still controversial area.
Sub-therapeutic Dosing In Pediatric Trials To Be Reviewed By FDA's Pediatric Ethics Subcommittee
Panel is called in to shed light in a growing but still controversial area.
"Black Box" For Protopic, Elidel Is "Blunt" But Necessary Instrument, Advisory Cmte. Says
Although noting that data suggesting a cancer risk from the topical eczema treatments is not definitive, the panel concludes that a black box warning is the best approach to discourage off-label use. A medication guide should also be mandated, the committee says.